{"id":"pneumovax23","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Injection site reactions (erythema, induration, soreness)"},{"rate":"1-5","effect":"Fever"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL22016","moleculeType":"Small molecule","molecularWeight":"498.57"},"_dailymed":{"setId":"4c97c74d-b6b5-4492-b7ed-e02c76cc8514","title":"PNEUMOVAX 23 (PNEUMOCOCCAL VACCINE POLYVALENT) INJECTION, SOLUTION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharide antigens from 23 different strains of pneumococcus. When administered, these antigens trigger B-cell and T-cell mediated immune responses, leading to the production of specific antibodies and memory cells that provide protection against pneumococcal infection. This helps prevent invasive pneumococcal diseases including pneumonia, bacteremia, and meningitis in vaccinated individuals.","oneSentence":"Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:23.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine"},{"name":"Prophylaxis in adults aged 50 years and older"},{"name":"Prophylaxis in high-risk populations including those with chronic diseases, immunocompromised states, or asplenia"}]},"trialDetails":[{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT05420961","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-12","conditions":"Pneumonia, Pneumococcal","enrollment":717},{"nctId":"NCT05633992","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-10","conditions":"Pneumococcal Disease","enrollment":450},{"nctId":"NCT05464420","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-12","conditions":"Pneumococcal Disease","enrollment":2162},{"nctId":"NCT04665050","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-04","conditions":"Pneumococcal Infection","enrollment":102},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT04168190","phase":"PHASE1, PHASE2","title":"A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-06","conditions":"Pneumonia, Pneumococcal","enrollment":600},{"nctId":"NCT03449459","phase":"EARLY_PHASE1","title":"Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-12-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":144},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT02225587","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-28","conditions":"Pneumococcal Infections","enrollment":400},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT02045836","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-05","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":865},{"nctId":"NCT01485406","phase":"PHASE1","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-12","conditions":"Infections, Streptococcal","enrollment":61},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT00907777","phase":"PHASE3","title":"Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-23","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":52},{"nctId":"NCT00307528","phase":"PHASE2","title":"Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-01-20","conditions":"Prophylaxis Invasive Pneumococcal Diseases and Pneumonia","enrollment":146},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT02260882","phase":"PHASE4","title":"Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-31","conditions":"Pneumococcal Infection","enrollment":243},{"nctId":"NCT01734239","phase":"PHASE3","title":"A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-03","conditions":"Pneumococcal Disease","enrollment":102},{"nctId":"NCT01153893","phase":"PHASE3","title":"Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Infections, Streptococcal","enrollment":105},{"nctId":"NCT02218697","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Influenza","enrollment":357},{"nctId":"NCT00756067","phase":"PHASE1","title":"Evaluation of Pneumococcal Vaccine Formulations in Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-19","conditions":"Infections, Streptococcal","enrollment":168},{"nctId":"NCT00707798","phase":"PHASE1","title":"Evaluation of Pneumococcal Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-30","conditions":"Infections, Streptococcal","enrollment":157},{"nctId":"NCT00327665","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Infections, Streptococcal","enrollment":335},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Herpes Zoster, Pneumococcal Infection","enrollment":473},{"nctId":"NCT00496093","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Pneumococcal Infection","enrollment":133},{"nctId":"NCT00307008","phase":"PHASE2","title":"Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Streptococcus Pneumoniae Vaccines","enrollment":1198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PPSV23","Pneumococcal polysaccharide vaccine","PPV23"],"phase":"marketed","status":"active","brandName":"Pneumovax™23","genericName":"Pneumovax™23","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pneumovax 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae bacteria. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis) caused by Streptococcus pneumoniae serotypes included in the vaccine, Prophylaxis in adults aged 50 years and older, Prophylaxis in high-risk populations including those with chronic diseases, immunocompromised states, or asplenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}